
|Articles|March 19, 2008
DEA exempts six anabolic steroid products from its regulatory control
The Drug Enforcement Administration is moving three anabolic steroid products out of Schedule III status.
Advertisement
Newsletter
Pharmacy practice is always changing. Stay ahead of the curve with the Drug Topics newsletter and get the latest drug information, industry trends, and patient care tips.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Drug Topics
1
American Pharmacists Month: Pharmacist Barriers, Expansion of Scope Since the COVID-19 Pandemic
2
Community Pharmacies Need to Better Prioritize Whole-Person Health Care | NCPA 2025
3
Pass-Through Rebate Law Uncovering New PBM Tactics, Entities | NCPA 2025
4
Automation Helps Pharmacies Maximize Revenue, Improve Patient Care | NCPA 2025
5


























































































































































